Keam Susan J
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand.
Drugs. 2025 May;85(5):699-706. doi: 10.1007/s40265-025-02160-6. Epub 2025 Apr 1.
Iparomlimab and tuvonralimab () is a bifunctional combination of anti-programmed death receptor-1 (PD-1)/anti-cytotoxic T lymphocyte-associated protein-4 (CTLA-4) monoclonal antibodies (mAbs) being developed by Qilu Pharmaceutical Co., Ltd for the treatment of advanced, solid, malignant tumours. In September 2024, iparomlimab and tuvonralimab was granted conditional approval (based on surrogate endpoints) for the treatment of patients with recurrent or metastatic cervical cancer who have failed previous platinum-based chemotherapy. This article summarizes the milestones in the development of iparomlimab and tuvonralimab leading to this first approval for the treatment of patients with recurrent or metastatic cervical cancer who have failed previous platinum-based chemotherapy.
帕罗利单抗和图沃利单抗（）是齐鲁制药有限公司正在研发的一种抗程序性死亡受体-1（PD-1）/抗细胞毒性T淋巴细胞相关蛋白-4（CTLA-4）单克隆抗体（mAbs）的双功能组合，用于治疗晚期实体恶性肿瘤。2024年9月，帕罗利单抗和图沃利单抗获得有条件批准（基于替代终点），用于治疗既往铂类化疗失败的复发性或转移性宫颈癌患者。本文总结了帕罗利单抗和图沃利单抗研发过程中的里程碑事件，这些事件促成了其首次获批用于治疗既往铂类化疗失败的复发性或转移性宫颈癌患者。
